Private equity firm Keensight Capital has agreed to acquire a majority stake in Isto Biologics, a US-based orthobiologics specialist, from Thompson Street Capital Partners in a deal valued at around $1bn according to a report by Bloomberg.
Thompson Street will retain a minority interest in the company, alongside Isto’s management team. The transaction ranks among Keensight’s largest healthcare investments to date and underscores continued momentum in mid-market private equity dealmaking.
Founded in 2016, Isto Biologics develops and manufactures orthobiologic products, including bone graft solutions and spine repair applications. The company supplies more than 400 hospitals and clinics across the US.
